Use of inotropic agents in patients with advanced heart failure: Lessons from recent trials and hopes for new agents

Drugs

Volumn 71, Issue 5, 2011, Pages 515-525

  Metra, Marco ^a   Bettari, Luca ^a   Carubelli, Valentina ^a   Bugatti, Silvia ^a   Cas, Alessandra Dei ^b   Del Magro, Francesca ^a   Lazzarini, Valentina ^a   Lombardi, Carlo ^a   Cas, Livio Dei ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Cardiotonics; Chronic heart failure; Digoxin; Dobutamine; Dopamine; Enoximone; Epoprostenol; Etomoxir; Istaroxime; Levosimendan; Milrinone; Omecamtiv mecarbil; Perhexiline; Ranolazine; Research and development; Trimetazidine; Urocortin

Indexed keywords

CALCIUM; CYCLIC AMP; DIGOXIN; INOTROPIC AGENT; MYOSIN;

CALCIUM TRANSPORT; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; HEART FAILURE; HEART MUSCLE METABOLISM; HEART OUTPUT; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEMODYNAMICS; HUMAN; REVIEW;

ANIMALS; CALCIUM; CARDIOTONIC AGENTS; CLINICAL TRIALS AS TOPIC; CYCLIC AMP; DRUG DESIGN; HEART FAILURE; HUMANS; TREATMENT OUTCOME;

EID: 79953206654     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11585480-000000000-00000     Document Type: Review

References (81)

1. MacIntyre K, Capewell S, Stewart S, et al. Evidence of improving prognosis in heart failure: trends in case fatality in 66,547 patients hospitalized between 1986 and 1995. Circulation 2000; 102: 1126-31.
2. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002; 347: 1397-402. (Pubitemid 35239711)
3. Dickstein K, Vardas PE, Auricchio A, et al. 2010 focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur J Heart Fail 2010; 12: 1143-53.
4. Metra M, Ponikowski P, Dickstein K, et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2007; 9: 684-94. (Pubitemid 46705572)
5. Cotter G, Metra M, Milo-Cotter O, et al. Fluid overload in acute heart failure: re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008; 10: 165-9. (Pubitemid 351222743)
6. Zile MR, Bennett TD, St John Sutton M, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 2008; 118: 1433-41.
7. Stevenson LW, Zile M, Bennett TD, et al. Chronic ambu- latory intracardiac pressures and future heart failure events. Circ Heart Fail 2010; 3: 580-7.
8. Stevenson LW. Are hemodynamic goals viable in tailoring heart failure therapy? Hemodynamic goals are relevant. Circulation 2006; 113: 1020-7.
9. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006; 296: 2217-26. (Pubitemid 44708052)
10. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: inotropic infusions during hospitalization. Circulation 2003; 108: 367-72. (Pubitemid 36899031)
11. Nieminen MS, Bohm M, Cowie MR, et al. Executive sum- mary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384-416. (Pubitemid 40283098)
12. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009; 53: 557-73.
13. Teerlink JR, Metra M, Zaca V, et al. Agents with inotropic properties for the management of acute heart failure syndromes: traditional agents and beyond. Heart Fail Rev 2009; 14: 243-53.
14. Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009; 28: 535-41.
15. Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA 2002; 287: 628-40. (Pubitemid 34252016)
16. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-89.
17. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: 1977-2016.
18. Lindenfeld J, Albert NM, Boehmer JP, et al. Executive summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16: 475-539.
19. Jaarsma T, Beattie JM, Ryder M, et al. Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2009; 11: 433-43.
20. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients. Description of population. Eur Heart J 2006; 27: 2725-36. (Pubitemid 44729876)
21. Abraham WT, Adams KF, Fonarow GC, et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005; 46: 57-64. (Pubitemid 40905130)
22. Leier CV, Binkley PF. Parenteral inotropic support for ad- vanced congestive heart failure. Prog Cardiovasc Dis 1998; 41: 207-24. (Pubitemid 29009200)
23. Beohar N, Erdogan AK, Lee DC, et al. Acute heart failure syndromes and coronary perfusion. J Am Coll Cardiol 2008; 52: 13-6. (Pubitemid 351852938)
24. Schulz R, Rose J, Martin C, et al. Development of short- term myocardial hibernation: its limitation by the severity of ischemia and inotropic stimulation. Circulation 1993; 88: 684-95. (Pubitemid 23228069)
25. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003; 41: 997-1003. (Pubitemid 36315544)
26. Captopril-Digoxin Multicenter Research Group. Com- parative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988; 259: 539-44.
27. Young JB, Gheorghiade M, Uretsky BF, et al. Superiority of "triple" drug therapy in heart failure: insights from the PROVED and RADIANCE trials. J Am Coll Cardiol 1998; 32: 686-92. (Pubitemid 28435254)
28. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-33.
29. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J 2006; 27: 178-86. (Pubitemid 43069034)
30. Ahmed A, Waagstein F, Pitt B, et al. Effectiveness of digoxin in reducing one year mortality in chronic heart failure in the Digoxin Investigation Group trial. Am J Cardiol 2009; 103: 82-7.
31. The Digitalis Investigation Group. Rationale, design, im- plementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Control Clin Trials 1996; 17: 77-97.
32. Gheorghiade M, Braunwald E. Reconsidering the role for digoxin in the management of acute heart failure syndromes. JAMA 2009 Nov 18; 302 (19): 2146-7.
33. Felker GM, O'Connor CM. Inotropic therapy for heart failure: an evidence-based approach. Am Heart J 2001; 142: 393-401. (Pubitemid 32801622)
34. O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999; 138: 78-86. (Pubitemid 29331125)
35. Thackray S, Easthaugh J, Fremantle N, et al. The effec- tiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure: meta-regression analysis. Eur J Heart Fail 2002; 4: 515-29. (Pubitemid 36564973)
36. Friedrich JO, Adhikari N, Herridge MS, et al. Meta-ana- lysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142: 510-24.
37. Dei Cas L, Metra M, Visioli O. Clinical pharmacology of inodilators. J Cardiovasc Pharmacol 1989; 14 Suppl. 8: S60-71. (Pubitemid 20056577)
38. Metra M, Nodari S, D'Aloia A, et al. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol 2002; 40: 1248-58.
39. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 2007; 153: 98-104. (Pubitemid 44880871)
40. Cuffe MS, Califf RM, Adams Jr KF, et al. Short-term in- travenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541-7. (Pubitemid 34269999)
41. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE Study Research Group. N Engl J Med 1991; 325: 1468-75.
42. Cohn JN, Goldstein SO, Greenberg BH, et al. A dose- dependent increase in mortality with vesnarinone among patients with severe heart failure: Vesnarinone Trial Investigators. N Engl J Med 1998; 339: 1810-6. (Pubitemid 29005785)
43. Uretsky BF, Jessup M, Konstam MA, et al. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circ 1990; 82: 774-80. (Pubitemid 20316728)
44. Metra M, Eichhorn E, Abraham WT, et al. Effects of low- dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur Heart J 2009; 30: 3015-26.
45. Pollesello P, Ovaska M, Kaivola J, et al. Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C: a molecular modelling, fluorescence probe and proton nuclear magnetic resonance study. J Biol Chem 1994 18; 269 (46): 28584-90.
46. Cleland JG, Freemantle N, Coletta AP, et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006; 8: 105-10. (Pubitemid 43012109)
47. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007; 297: 1883-91. (Pubitemid 46707842)
48. Mebazaa A, Nieminen MS, Filippatos GS, et al. Levosi- mendan vs. dobutamine: outcomes for acute heart failure patients on b-blockers in SURVIVE. Eur J Heart Fail 2009; 11: 304-11.
49. Nieminen MS, Cleland JG, Eha J, et al. Oral levosimendan in patients with severe chronic heart failure: the PERSIST study. Eur J Heart Fail 2008; 10: 1246-54.
50. Khan H, Metra M, Blair JE, et al. Istaroxime, a first in class new chemical entity exhibiting SERCA-2 activation and Na-K-ATPase inhibition: a new promising treatment for acute heart failure syndromes? Heart Fail Rev 2009; 14: 277-87.
51. Gheorghiade M, Blair JE, Filippatos GS, et al. Hemody- namic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol 2008; 51: 2276-85.
52. Shah SJ, Blair JE, Filippatos GS, et al. Effects of istaroxime on diastolic stiffness in acute heart failure syndromes: results from the Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled Trial in Patients Hospitalized with Heart Failure (HORIZON-heart failure) trial. Am Heart J 2009; 157: 1035-41.
53. Dec GW. Istaroxime in heart failure: new hope or more hype. J Am Coll Cardiol 2008; 51: 2286-8.
54. Teerlink JR. A novel approach to improve cardiac perfor- mance: cardiac myosin activators. Heart Fail Rev 2009; 14: 289-98.
55. Shen YT, Malik FI, Zhao X, et al. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. Circ Heart Fail 2010; 3: 522-7.
56. Bax JJ, Casadei B, Di Mario C, et al. Highlights of the 2009 scientific sessions of the European Society of Cardiology. J Am Coll Cardiol 2009; 54: 2447-58.
57. Vaughan J, Donaldson C, Bittencourt J, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 1995; 378: 287-92.
58. Rademaker MT, Cameron VA, Charles CJ, et al. Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure. Circulation 2005; 112: 3624-32. (Pubitemid 43739541)
59. Rademaker MT, Charles CJ, Espiner EA, et al. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol 2002; 40: 1495-505. (Pubitemid 35192877)
60. Rademaker MT, Cameron VA, Charles CJ, et al. Urocortin 3: haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J 2006; 27: 2088-98. (Pubitemid 44412817)
61. Rademaker MT, Charles CJ, Nicholls MG, et al. Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure. Circ Heart Fail 2009; 2: 532-40.
62. Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur Heart J 2004; 25: 634-41. (Pubitemid 38579491)
63. Soukoulis V, Dihu JB, Sole M, et al. Micronutrient defi- ciencies an unmet need in heart failure. J Am Coll Cardiol 2009; 54: 1660-73.
64. Opie LH, Knuuti J. The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol 2009; 54: 1637-46.
65. Horowitz JD, Chirkov YY, Kennedy JA, et al. Modulation of myocardial metabolism: an emerging therapeutic principle. Curr Opin Cardiol 2010; 25: 329-34.
66. Killalea SM, Krum H. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am J Cardiovasc Drugs 2001; 1: 193-204.
67. Lee L, Campbell R, Scheuermann-Freestone M, et al. Me- tabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005; 112: 3280-8. (Pubitemid 43739373)
68. Fragasso G, Piatti Md PM, Monti L, et al. Short- and long- term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003; 146: E18.
69. Fragasso G, Palloshi A, Puccetti P, et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxi- dation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006; 48: 992-8. (Pubitemid 44292461)
70. Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008; 118: 1250-8.
71. Di Napoli P, Di Giovanni P, Gaeta MA, et al. Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial. J Cardio-vasc Pharmacol 2007; 50: 585-9. (Pubitemid 350146463)
72. Fragasso G, Perseghin G, De Cobelli F, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006; 27: 942-8.
73. Sossalla S, Wagner S, Rasenack EC, et al. Ranolazine im- proves diastolic dysfunction in isolated myocardium from failing human hearts: role of late sodium current and in-tracellular ion accumulation. J Mol Cell Cardiol 2008; 45: 32-43.
74. Wu Y, Song Y, Belardinelli L, et al. The late Na+ current (INa) inhibitor ranolazine attenuates effects of palmitoyl-L-carnitine to increase late INa and cause ventricular dia-stolic dysfunction. J Pharmacol Exp Ther 2009; 330: 550-7.
75. Rastogi S, Sharov VG, Mishra S, et al. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. Am J Physiol Heart Circ Physiol 2008; 295: H2149-55.
76. Nikolaidis LA, Elahi D, Hentosz T, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110: 955-61. (Pubitemid 39128621)
77. Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006; 12: 694-9. (Pubitemid 44881367)
78. Halbirk M, Nørrelund H, Møller N, et al. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 2010; 298: H1096-102.
79. Lehnart SE, Maier LS, Hasenfuss G. Abnormalities of cal- cium metabolism and myocardial contractility depression in the failing heart. Heart Fail Rev 2009; 14 (4): 213-24.
80. Jaski BE, Jessup ML, Mancini DM, et al. Calcium upregu- lation by percutaneous administration of gene therapy in cardiac disease (CUPID trial), a first-in-human phase 1/2 clinical trial. J Card Fail 2009; 15: 171-81.
81. Rengo G, Lymperopoulos A, Leosco D, et al. GRK2 as a novel gene therapy target in heart failure. J Mol Cell Car-diol. Epub 2010 Aug 25